How it works:
Tenofovir Alafenamide (TAF) is a prodrug of tenofovir that becomes active inside infected cells. It inhibits the reverse transcriptase enzyme, blocking viral replication in HIV and HBV. Compared to previous forms, TAF achieves effective results at lower doses with a reduced risk of kidney and bone side effects.
Recommended for:
Adults and adolescents with HIV-1 (in combination therapy)
Patients with chronic hepatitis B
Individuals at risk of renal or bone toxicity
Only for patients aged 12 and older under medical supervision
Treatment of HIV-1 infection in adults and adolescents as part of combination therapy
Treatment of chronic hepatitis B
The tablets are taken orally once daily, with or without food. Dosage and duration should be determined by the healthcare provider based on clinical condition and therapy regimen.
Hypersensitivity to tenofovir or any component of the product
Severe renal impairment
Children under 12 years (unless specifically prescribed)
Pregnancy and breastfeeding without medical advice
Headache, fatigue
Nausea, abdominal pain
Increased cholesterol levels
Reduced bone mineral density
Rare renal function disturbances
Skin rash or allergic reactions
